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INTRODUCTION
Third trimester pregnancy significantly induces in vivo CYP3A activity as measured by midazolam oral clearance (~2-fold; (Hebert et al., 2008) . This induction can result in subtherapeutic plasma concentrations of drugs. For example, the oral clearance of the HIV protease inhibitor, indinavir, a CYP3A substrate, is much greater (~3-fold) during the 3 rd trimester than post-partum (or in non-pregnant women or men) .
Similarly, pregnancy induces hepatic Cyp3a activity in mice (~3-fold). This induction is due to increased transcription of Cyp3a isoforms Cyp3a41 (the dominant Cyp3a isoform in female mice), Cyp3a16 and Cyp3a44, resulting in increased Cyp3a protein expression (Zhang et al., 2008) . Moreover, pregnancy transcriptionally activates mouse Cyp3a isoforms and the human CYP3A4 promoter in the liver (but not in the intestine) of pregnant CYP3A4-promoter-luciferase transgenic (CYP3A4-tg) mice (Zhang et al., 2008) . Although the above studies demonstrate that pregnancy induces CYP3A/3a activity by transcriptional activation of CYP3A4/Cyp3a enzymes, the hormones and mechanisms responsible for this induction are not known. In this manuscript, we report for the first time studies in sandwich-cultured human hepatocytes (SCHH) and hepatic cell lines that identify the responsible hormones.
While the plasma concentration of several hormones is increased during pregnancy, evidence in the literature (as detailed below) suggests that only four of these: pituitary growth hormone (GH), cortisol (C), estradiol (E2), and progesterone (P) have the potential to modulate hepatic CYP3A activity. There are considerable data to show that GH regulates CYP3A activity in humans. When hepatocytes (from male and female donors) are exposed to the feminine-like continuous GH profile, CYP3A activity and expression (protein and mRNA) are induced (Dhir et al., 2006) . Similarly, GH replacement in GH-deficient individuals, restores CYP3A4 activity (as measured by erythromycin breath test) to levels observed in healthy individuals (Jaffe et al., 2002) . In humans, as pregnancy proceeds, the continuous secretion of placental growth hormone (PGH) by the placenta gradually replaces (Table 1 ) which remains at a constant low concentration from midgestation onwards (Igout et al., 1995) . PGH differs from GH by only 13 amino acid residues (Frankenne et al., 1988) , but they both bind with similar affinity to the growth hormone receptor (GHR) (Baumann et al., 1991) and activate the same signaling pathways (Silva et al., 2002) . However, the effect of PGH on hepatic CYP3A activity has never been investigated. Here we report for the first time the effect of PGH on CYP3A activity and expression in SCHH and hepatic cell lines. The major circulating corticosteroid in humans is cortisol while in mice it is corticosterone (Barlow et al., 1973) . In humans (Table 1 ) and mice, the serum concentrations of these corticosteroids increase during pregnancy.
Corticosteroids are well known inducers of hepatic CYP3A/3a expression (Pascussi et al., 2001 ). Hepatic expression of the female-predominant Cyp3a41 isoform depends on estradiol plasma concentrations in female non-pregnant mice (Yamada et al., 2002) .
Administration of medroxyprogesterone acetate to post-menopausal women increases CYP3A activity as measured by the erythromycin breath test (Tsunoda et al., 1998) .
Since the concentrations of the above hormones is increased during pregnancy, it is critical to identify which hormones, alone or in combination, induce hepatic CYP3A enzymes at their circulating plasma concentrations during pregnancy. Therefore, we studied the induction of CYP3A enzymes (activity and expression) by pregnancy-related hormones in SCHH at the circulating plasma concentrations (total or 1X and unbound) of these hormones and also ten-fold their total plasma concentrations (10X). Furthermore, we determined whether the pregnancy hormone mediated induction of CYP3A observed in SCHH could be replicated in the commercially available human hepatic cell lines, HepG2, Huh7, and HepaRG. If it is, these cells could be used in the future to elucidate the mechanistic basis of this induction.
MATERIALS AND METHODS
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Chemicals and reagents
Growth hormone, 17β-estradiol, estriol, cortisol, progesterone, and testosterone were purchased from Sigma-Aldrich (St. Louis, MO); placental growth hormone was purchased from GenWay Biotech. Inc (San Diego, CA). Midazolam was purchased from Cerilliant Corporation (Round Rock, TX). Acetic acid (ACS grade) and methanol (Optima grade) were purchased from Fisher Scientific (Pittsburgh, PA).
Primary human hepatocytes and Hormone Treatment
Stock solutions of rifampin (10 μM), estradiol, cortisol, progesterone, estriol, and testosterone were prepared in methanol; growth hormone and placental growth hormone were diluted in dH 2 O, pH=9. In all subsequent experiments the cells were treated at 37 o C, 5% CO 2 for 72h with vehicle (0.1% dH 2 O, pH=9 and 0.9% methanol) or the pregnancyspecific hormones (individually or in combinations) at the unbound, total, and 10X-total 3 rd trimester plasma concentrations (Table 1) . In all experiments, incubations with 10 M rifampin were always included as an internal biological control. Medium containing the hormones or rifampin was changed every 24h. All incubations were performed in triplicate.
Primary human hepatocytes. Cryopreserved or freshly isolated SCHH from healthy female donors (Table 2) were obtained commercially (Life Technologies, Carlsbad, CA).
Hepatocytes were plated in collagen-coated 96-well plates according to the manufacturer's instructions. The cells were maintained (37 o C, 5% CO 2 ) in incubation medium which consists of Williams E medium supplemented with serum-free Hepatocyte Maintenance Supplements (Life Technologies, Carlsbad, CA). The only difference from the manufacturer's protocol was that we excluded the marginal amount of dexamethasone normally included in the incubation medium, which is not critical for maintaining cell health.
After 72h, the SCHH were incubated without or with the pregnancy hormone(s) at the unbound, total, and 10X-total 3 rd trimester plasma concentrations. During culture, morphological changes, if any, of the SCHH were examined by a phase contrast 
CYP3A Activity Measurement
At the end of the incubations, CYP3A activity in SCHH and HepaRG cells was measured using midazolam as a probe drug. Briefly, after the third day, culture medium was aspirated;
the cells were rinsed twice with pre-warmed PBS and were incubated ( .
Isolation of RNA and measurement of CYP3A4/5 mRNA expression by real-time PCR (qPCR)
At the end of the hormone treatments, total RNA was extracted (as per the manufacturer's instructions) from SCHH and HepaRG cells using the Ambion RNAqueous 9
Master Mix and TaqMan primer-probe mixes were purchased from Applied Biosystems Inc.
for the detection of human mRNA sequences for CYP3A4 (Hs00430021_m1), CYP3A5 (Hs00241417_m1), estrogen receptor alpha (ERα; Hs00174860_m1), glucocorticoid receptor (GR; Hs00353740_m1), growth hormone receptor (GHR; Hs00174872_m1), and β-glucuronidase (GUS; Hs00939627_m1). Because the concentration of methanol used in the hormone treatments (0.9%) might promote changes in gene expression, the mRNA levels of the studied genes in the presence and absence of methanol (in the absence of the hormones) was compared and found not to be different (data not shown). In all cases, qPCR reactions and analysis of the results were performed as described previously (Dixit et al., 2007) .
Statistical and Data Analysis
CYP3A activity and mRNA levels in the treated groups were expressed relative to that observed in the vehicle control (negative control). One-way analysis of variance was used when multiple comparisons were made, followed by Tukey's Multiple Comparison Test 
RESULTS
The effect of PGH, GH, cortisol, and progesterone on CYP3A4 mRNA expression and activity in SCHH from post-menopausal and pre-menopausal women
To establish that pregnancy hormones can indeed induce CYP3A4 and to determine the effect of dexamethasone on this induction, we conducted the following preliminary studies.
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Cryopreserved SCHH from three post-menopausal donors (Hu0737, Hu1037, and Hu4152 - Table 2) were incubated with PGH, GH, cortisol, and progesterone (individually or in combinations) at the 10X-total 3 rd trimester plasma concentrations (Table 1) . We included the 10X-total concentration in our experiments to provide a measure of CYP3A induction produced at this supraphysiological concentration against which induction at lower but physiological concentrations can be compared. For two of these donors (Hu0737, Hu1037), the incubations were performed in the absence and presence of dexamethasone (100 nM), an agent which is traditionally included in hepatocyte incubations. CYP3A4 induction was measured by the most sensitive index available i.e. CYP3A4 mRNA. In the presence of dexamethasone, as expected, rifampin induced the expression of CYP3A4 transcripts by ~14-fold but not at all by any of the pregnancy hormones or their combinations (data not shown). In contrast, in the absence of dexamethasone, of all the hormones incubated individually, only cortisol consistently and significantly induced CYP3A4 mRNA expression (Fig. 1Α) . Progesterone was able to induce CYP3A4 expression in only one donor (Fig. 1Α ).
The combination of the growth hormones (GHs, i.e. PGH and GH) plus cortisol (but not GHs+progesterone) consistently and significantly induced CYP3A4 mRNA expression greater than cortisol alone (Fig. 1A) . In addition, the combination of cortisol and progesterone consistently and significantly induced CYP3A4 greater than progesterone or cortisol alone (Fig. 1A) . Rifampin induced CYP3A4 mRNA expression by ~90-340 fold.
Given that in the absence of dexamethasone the pregnancy hormones dramatically and significantly induced CYP3A4 transcripts, all subsequent experiments detailed below were conducted without dexamethasone.
We confirmed that the above observations, with respect to CYP3A activity and mRNA expression, were mostly replicated in SCHH from a pre-menopausal female (Hu8116 - Table 2 ) incubated with 1X-total and 10X-total plasma concentrations of the hormones.
Similar to that observed with post-menopausal donors, cortisol induced CYP3A activity and CYP3A4 mRNA expression in these SCHH at both the concentrations used ( Figs 1B, 1C ).
This article has not been copyedited and formatted. The final version may differ from this version. (Figs. 1B, 1C) . Moreover, the combination of cortisol and progesterone consistently and significantly induced CYP3A activity and CYP3A4 mRNA greater than progesterone or cortisol alone (Figs. 1B, 1C ). Rifampin induced CYP3A activity (~15-fold) and CYP3A4 mRNA (~120-fold).
Effect of pregnancy-related hormones on CYP3A activity and CYP3A4/5 expression in
pre-menopausal SCHH
To conduct a detailed study of the role of the pregnancy-related hormones in the induction of CYP3A enzymes, we expanded the above study as follows: 1) estradiol, estriol and testosterone were included in the panel of hormones studied; 2) three different concentrations of the hormones were studied, namely the unbound, total, and 10X-total 3 rd trimester plasma concentrations. Only PGH was studied at the unbound 3 rd trimester plasma concentrations as the unbound plasma concentrations of the GH in the period is negligible; 3) CYP3A activity as well as CYP3A4 and CYP3A5 transcripts were quantified; 4) the transcripts of the receptors of these hormones were quantified, namely estrogen receptor alpha (ERα), glucocorticoid receptor (GR), and growth hormone receptor (GHR). These studies were conducted in three different donors of SCHH. Results from only two donors (Hu4197, Hu4232 - Table 2 ) are presented below because, for the third donor (Hu8130 - and CYP3A4 mRNA to levels surpassing those induced by cortisol alone (Figs. 2 and 3) .
However, the same combination did not consistently induce CYP3A5 mRNA more than cortisol alone (Fig. 4) . When the induction by C+P vs. C or E2+C vs. C was compared, no consistent pattern emerged. However, as was observed for the post-menopausal SCHH, at 10x-total 3 rd trimester plasma concentration, C+P induced CYP3A activity more than C alone. Except for those discussed below, all other combination of hormones did not consistently or significantly induce CYP3A activity or CYP3A4/5 mRNA expression.
The combined treatment with the five hormones (PGH, GH, estradiol, cortisol, progesterone) at the unbound, total, and 10X-total 3 rd trimester plasma concentrations induced CYP3A activity and CYP3A4/5 expression (Figs. 2, 3 , and 4). Moreover, this induction was not significantly different from that observed when estriol and testosterone were included (data not shown). The combination of all the hormones (GHs+E2+C+P), at the unbound or total 3 rd trimester plasma concentrations of the hormones, induced CYP3A activity (but not CYP3A4 expression) to a lesser extent than GHs+C, suggesting that at these concentrations, E2 or P or both suppress the induction caused by GHs+C (Figs. 2 and 3). Interestingly, the fold-induction in CYP3A activity produced by the combined unbound or total 3 rd trimester hormone plasma concentrations was ~2-4 fold ( Fig. 2A, B) . Rifampin induced CYP3A activity by ~14-25 fold, CYP3A4 expression by ~85-250 fold, and CYP3A5 expression by ~3-4 fold. The ability of the hormones to induce CYP3A activity was strongly and significantly correlated with the induction of CYP3A4 transcripts (r s = 0.825, p < 0.001).
In addition the induction of CYP3A5 transcripts under all the hormonal treatments was strongly and significantly correlated with that of CYP3A4 (r s = 0.801, p < 0.001).
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Effect of pregnancy-related hormones on estrogen receptor alpha (ERα), growth hormone receptor (GHR), and glucocorticoid receptor (GR) mRNA expression in SCHH
We investigated the effect of pregnancy-related hormones on the expression of the respective hormone receptors using qPCR. Of the two estrogen receptor isoforms (alpha and beta; ERα and ERβ), we chose to determine the expression of ERα since it is the only one which is expressed in adult human hepatocytes (Taylor and Al-Azzawi, 2000) . Of all the hormones incubated individually, only estradiol at the total and 10X-total 3 rd trimester plasma concentrations, consistently induced ERα mRNA expression (Fig. 5) . Additionally the combination of the GHs and estradiol at the total and 10X-total plasma 3 rd trimester concentrations consistently and significantly induced ERα mRNA expression, exceeding those induced by estradiol alone (Fig. 5B, 5C ). Interestingly under certain hormone treatments (Fig. 5) , ERα expression decreased compared to control. For example, at the 1X-and 10X-total 3 rd trimester plasma concentrations of the hormones, GHs+C+E2 or GHs+C+E2+P induced ERα expression to a lesser degree than GHs+E2. In addition, all the hormone treatments had a modest or no effect on the expression of GHR and GR (Supplemental Figures 1 and 2 ).
Effect of pregnancy-related hormones on CYP3A4 expression in HepG2 and Huh7 cells
To examine whether the hormone-mediated changes in CYP3A4 expression that were observed in SCHH could be replicated in a commercially available human hepatic cell lines, we incubated HepG2 and DMSO-treated Huh7 cells with the 10X-total 3 rd trimester plasma concentrations of PGH, GH, estradiol, cortisol, and progesterone (individually or in various combinations). We chose to use DMSO-treated Huh7 cells for these experiments, since it This article has not been copyedited and formatted. The final version may differ from this version. (Sivertsson et al., 2010) . Additionally we decided to determine only the fold-induction in CYP3A4 transcripts as it was a more sensitive measure of CYP3A induction in SCHH (Figs. 2 and 3) . In HepG2 cells the expression of CYP3A4 transcripts was very low, thus we could not determine any hormonemediated induction of CYP3A4 transcript expression in these cells. In Huh7 cells, of all the hormones incubated individually (PGH, GH, estradiol, cortisol, and progesterone) only cortisol consistently induced CYP3A4 mRNA levels at the 10X-total 3 rd trimester plasma concentrations (Fig. 6A) . The combination of GHs plus cortisol induced CYP3A4 mRNA levels even further (~30% increase). Moreover, the combination of cortisol with estradiol induced CYP3A4 transcripts greater than that observed after exposure to estradiol or cortisol alone (Fig. 6A) . Finally, the combined treatment with the five pregnancy-specific hormones significantly induced CYP3A4 mRNA levels but to a lesser extent than E2+C or GHs+C (Fig.   6A ).
Effect of pregnancy-related hormones on CYP3A activity and CYP3A4 expression in
HepaRG cells
The incubation of HepaRG cells with the pregnancy-specific hormones was performed in the presence and absence of hydrocortisone hemisuccinate, an agent which is normally included in the manufacturer-provided supplements (Steen D., personal communication).
However, in the presence of hydrocortisone hemisuccinate, none of the hormones were able to produce a measurable and significant change in CYP3A activity but rifampin did induce Of all the hormones incubated individually, only cortisol consistently and significantly induced CYP3A activity and CYP3A4 mRNA expression (Fig. 6B, 6C ). The combination of the GHs plus cortisol consistently and significantly induced CYP3A activity and CYP3A4
transcripts to levels surpassing those induced by the glucocorticoid alone (Fig. 6B, 6C ).
Finally, the combined treatment with the five pregnancy-specific hormones (PGH, GH, estradiol, cortisol, and progesterone) consistently and significantly induced CYP3A activity and CYP3A4 expression to a level not significantly different from GHs+C (Fig. 6B, 6C ).
Rifampin induced CYP3A activity by ~20 fold and CYP3A4 expression levels by ~120 fold (data not shown).
DISCUSSION
We found that of all the hormones incubated individually, only cortisol consistently and significantly induced CYP3A activity and CYP3A4 expression in SCHH. These results are in agreement with in vivo studies in mice, which have shown that adrenalectomy decreases hepatic expression of the female-predominant Cyp3a41 (Sakuma et al., 2004) . This phenotype could be reversed only after dexamethasone administration. Even though corticosteroids induce CYP3A4, literature data are contradictory on the involvement of GR or PXR in this induction. Using GR(-/-) mice, Schuetz et al., (Schuetz et al., 2000) have shown that induction of CYP3a by dexamethasone is independent of GR. This induction, at physiological concentrations of cortisol, is also independent of PXR (pregnane X receptor).
Cortisol activates human PXR at very high μΜ concentrations (Blumberg et al., 1998; Mnif et al., 2007) , concentration which are considerably higher than the plasma concentrations of cortisol during human pregnancy (Table 1) . When rat hepatocytes, transfected with reporter constructs containing the human CYP3A4 promoter and the human PXR, are exposed to 10 μΜ cortisol, a concentration which far exceeds that observed in pregnant women (Table 1) , the expression of the reporter CYP3A construct is not induced (Xie et al., 2000) . Moreover, Cyp3a11 induction by oral administration of dexamethasone was not eliminated in PXR knock-out mice (Zimmermann et al., 2009 ). Therefore, cortisol-mediated induction of CYP3A4 seems to occur by an unknown PXR-independent mechanism(s).
The combination of the two growth hormone isoforms plus cortisol induced CYP3A activity and CYP3A4 mRNA expression greater than that observed after exposure to cortisol alone. This pattern of induction was identical between pre-menopausal and postmenopausal donors (Figs. 1A, 1C) indicating that SCHH from both sources of donors could be used for gain insight into the mechanisms of CYP3A induction by these hormones. This difference in induction by a glucocorticoid in the absence and presence of GH is in agreement with previous studies in human hepatocytes (Dhir et al., 2006; Thangavel et al., 2011) . In this regard, our results indicate that PGH behaves very much like GH. Given, that PGH gradually replaces the pituitary GH isoform throughout gestation, and it is continuously secreted, our findings indicate the potential role of PGH in combination with glucocorticoids, in regulating hepatic CYP3A activity in pregnant women. Interestingly, continuous exposure of human hepatocytes to GHs (feminine circulating pattern) and corticosteroids induces CYP3A4 protein to a greater extent in hepatocytes derived from female compared with male subjects (Thangavel et al., 2011) . This is due to greater activation and nuclear translocation of the transcriptional factors HNF-4α and PXR and enhanced binding of these factors to the CYP3A4 regulatory motifs (Thangavel et al., 2011) . In addition, the combination of cortisol and progesterone consistently and significantly induced CYP3A activity and CYP3A4 mRNA greater than progesterone or cortisol alone in both post-and pre-menopausal donors (Figs. 1, 3C), thus supporting the notion that the mechanisms of CYP3A induction is common between the two types of donors.
When compared with cortisol, the effect of PGH, GH, estradiol, progesterone, estriol, and testosterone (when incubated individually) in inducing hepatic CYP3A activity and expression was modest. Estradiol was not able to induce hepatic CYP3A activity or CYP3A4/5 transcripts at any of the concentrations used. Progesterone was a less potent inducer compared to cortisol since it was able to generate a statistically significant effect on CYP3A activity and CYP3A4 transcripts in only a few cases. This lack of effect may be due to rapid depletion of these steroids from the incubation medium as previously reported . In their study, even when the medium was changed frequently to compensate for this depletion, estradiol or progesterone, at the 10X-total 3 rd trimester plasma concentrations, resulted in a maximum 3-fold induction of CYP3A activity in some of their SCHH Koh et al., 2012) . Moreover administration of medroxyprogesterone acetate to post-menopausal women results in a modest increase (23-25%) in in vivo CYP3A activity as determined by prednisolone clearance (Tsunoda et al., 1998) . Collectively, these data suggest modest individual contribution of estradiol and progesterone on in vivo induction of CYP3A activity in SCHH.
Despite the modest individual contribution of estradiol and progesterone in inducing hepatic CYP3A activity and expression, their combination with the GHs (or PGH at the unbound plasma concentration observed during the 3 rd trimester) and cortisol consistently and significantly induced CYP3A activity and CYP3A4 transcripts. Interestingly this combination at the unbound and 1X 3 rd trimester plasma concentrations induced CYP3A activity by ~2-4 fold, a value which is comparable to the in vivo induction of CYP3A activity (as measured by midazolam oral clearance) during the 3 rd trimester (~2-fold) (Hebert et al., 2008) . To our knowledge, this in vitro to in vivo correspondence implies that SCHH, when incubated with PGH, GH, estradiol, cortisol, and progesterone (at the unbound and total 3 rd trimester plasma concentrations), can mimic the changes observed in hepatic CYP3A activity during the 3 rd trimester. Additional in vitro studies are required to determine the potency of these hormones at the lower concentrations observed in early gestation to induce hepatic CYP3A activity. Moreover the combination of all the hormones (GHs+E2+C+P), at the unbound or total 3 rd trimester plasma concentrations of the hormones, induced CYP3A activity to a lesser extent than GHs+C, suggesting that at these concentrations E2 or P or both suppress the induction caused by GHs+C. Further studies are needed to confirm and elucidate the mechanistic basis of this suppression. Furthermore, CYP3A activity and the expression of CYP3A4 transcripts in the SCHH exhibited a strong and significant correlation (r s = 0.825, p < 0.001). Thus, either CYP3A activity or CYP3A4 mRNA could be used as markers of hepatic CYP3A induction by pregnancy-related hormones in SCHH.
Cortisol was also the main inducer of CYP3A5 expression levels even though the observed fold-induction of CYP3A5 transcripts was modest. Moreover there was a strong correlation (r s = 0.801, p < 0.001) between the expression of the transcripts of these two CYP3A isoforms. Thus, despite the lower magnitude of induction of CYP3A5 vs. CYP3A4 transcripts, the strong correlation in the expression of these two transcripts suggests a commonality in the regulatory mechanisms of their induction.
The hormones had only a modest effect on the expression of the respective hormone receptors (GHR, GR, and ERα). Thus, this does not appear to be a primary mechanism by which the pregnancy-related hormones induce CYP3A activity. However, these results do not necessarily preclude the involvement of these receptors in pregnancy-induced CYP3A (Hart et al., 2010) . Although the fold-induction of CYP3A4 transcripts in HepaRG cells by the pregnancy-related hormones was larger than that in human hepatocytes, the pattern was similar except that, at the 1X-total 3 rd trimester plasma concentrations, the combination of five hormones did not suppress CYP3A activity when compared with GHs+C. Thus, our results suggest that HepaRG cells could serve as a readily available, cost-effective, in vitro model, to gain further insight into the mechanistic basis for the hormone-mediated induction of CYP3A4.
In summary, our data show that cortisol alone or in combination with GHs is a potent inducer of CYP3A activity and CYP3A4, CYP3A5 expression in SCHH, including at their physiologically relevant 3 rd trimester unbound plasma concentrations. The combination of cortisol and GH induced CYP3A activity and CYP3A4 transcripts greater than cortisol alone.
Additional experiments will need to be conducted to confirm whether there is synergy between cortisol and GH in the induction of CYP3A activity and transcripts. Our experiments also showed that PGH and GH are equally effective, when combined with cortisol, in inducing CYP3A activity. In addition, we have shown for the first time that the combination of all the pregnancy-specific hormones at their physiologic (unbound, total) plasma concentrations induce CYP3A activity in SCHH comparable to that observed in vivo.
This finding is important for several reasons. First, this suggests that the SCHH could be used to predict the magnitude of in vivo CYP3A induction earlier in gestation when
This article has not been copyedited and formatted. The final version may differ from this version. (Zhang et al., 2003) . We confirmed this observation in humans through sensitivity analysis of physiologically based pharmacokinetic modeling of disposition of CYP3A substrate drugs that have low to high intestinal first pass effect (Ban Ke et al., (in press)). Second, the SCHH could be used in the future to elucidate the molecular mechanisms of induction of in vivo CYP3A activity. Last, but not least, we have identified HepaRG cells as an in vitro model that could potentially be used to determine the role of hormone receptors and transcription factors in the hormone-mediated induction of CYP3A4 expression during pregnancy.
